+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Influenza Vaccine Market - Forecasts from 2019 to 2024

  • ID: 4756625
  • Report
  • 105 pages
  • Knowledge Sourcing Intelligence LLP
1 of 4

FEATURED COMPANIES

  • BioDiem
  • CSL Limited
  • F. Hoffmann-La Roche Ltd
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline plc.
  • Novavax, Inc.
  • MORE
The global influenza vaccine market is projected to grow at a CAGR of 6.37% to reach US$7.547 billion by 2024, from US$5.209 billion in 2018. Due to the constant changing of circulating influenza viruses, influenza vaccines strains are changed annually (for both the Northern Hemisphere and the Southern Hemisphere) to more closely match currently circulating virus strains (source: WHO). Hence the rising R&D expenditure and advancements in vaccine technology are driving the growth of the global influenza vaccine market in the forecast period. Furthermore, growing immunization for the prevention of influenza virus infection will emanate the market growth in the coming years and beyond.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global influenza vaccine value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global influenza vaccine market.

Major industry players profiled as part of the report are Seqirus, GlaxoSmithKline plc., Sanofi Pasteur SA., Novavax, Inc., Emergent BioSolutions Inc. among others.

Segmentation

The global influenza vaccine market has been analyzed through following segments:

By Vaccine Technology

Trivalent
Quadrivalent

By End-User

Children
Adolescents
Adults
Elderly

By Geography

North America
USA
Canada
Mexico
Others

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioDiem
  • CSL Limited
  • F. Hoffmann-La Roche Ltd
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline plc.
  • Novavax, Inc.
  • MORE
1. Introduction
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base and Forecast Years Timeline

2. Research Methodology
2.1. Research Design
2.2. Secondary Sources

3. Executive Summary

4. Market Dynamics
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry In the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. Global Influenza Vaccine Market by Vaccine Technology
5.1. Trivalent
5.2. Quadrivalent

6. Global Influenza Vaccine Market by End-User
6.1. Children
6.2. Adolescents
6.3. Adults
6.4. Elderly

7. Global Influenza Vaccine Market by Geography
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others

8. Competitive Intelligence
8.1. Competition and Offerings Analysis of Key Vendors
8.2. Recent Investment and Deals
8.3. Strategies of Key Players

9. Company Profiles
9.1. Seqirus
9.2. Glaxosmithkline Plc.
9.3. Sanofi Pasteur Sa.
9.4. Novavax, Inc.
9.5. Emergent Biosolutions Inc.
9.6. Csl Limited
9.7. Pfizer Limited
9.8. Gamma Vaccines Pty Ltd
9.9. Biodiem
9.10. F. Hoffmann-La Roche Ltd

List of Figures
List of Tables
Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Seqirus
  • GlaxoSmithKline plc.
  • Sanofi Pasteur SA.
  • Novavax, Inc.
  • Emergent BioSolutions Inc.
  • CSL Limited
  • Pfizer Limited
  • Gamma Vaccines Pty Ltd
  • BioDiem
  • F. Hoffmann-La Roche Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4756625
Adroll
adroll